Insufficient Quality System leads to GDP Non-Compliance Report
![GDP in Switzerland (GDP 3)](files/eca/userImages/training.img/Z-GDP3-GDP-in-Switzerland-neues-Layout.jpg)
Recommendation
12 September 2024
Basel, Switzerland
Specifics in the Distribution of Medicinal Products (Course in english language!)
Chapter 1 of the EU GDP-Guidelines (Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use) requires a Quality System. In general, the Quality System should have written procedures e.g. in the Quality Manual and in SOPs, about how each requirement of the EU GDP-Guidelines will be implemented in the company.
Thus, wholesalers must ensure that their Quality Management Systems (QMS) is aligned with the GDP requirement. Otherwise, this can lead to a GDP Non-Compliance Report, as a recent example shows.
The competent authority of Romania (National Agency for Medicines and Medical Devices of Romania) has entered a new GPD Non-Compliance Report dated 22 January 2021 into the EudraGMDP database.
During an inspection conducted in November 2020, it came out that the company does not comply with the GDP principles on several aspects. The Romanian authority lists the following failures:
- No change control system has been implemented.
- Deviations were not documented.
- No self-inspections were performed.
- Information on staff training could not be provided.
As a consequence, the wholesale permission was suspended.
Based on the information gained during the inspection, the company only supplied medicines to Romanian customers. According to the authority, there is no need to recall the medicines distributed by this wholesaler.
Source: EudraGMDP Database (Inspection Date: 12 November 2021; Report Number: NCD/010/RO) *
* To find the respective report, please click on "Non-Compliance Reports" in the menu on the left-hand side and select in "From Date / To Date" the month the inspection took place. After clicking on "Search" the results list will be displayed, from which you can choose the report with the number mentioned above.
Related GMP News
24.07.2024FDA Warning Letter to a Manufacturer of an Athlete Muscle Maintenance Creme
24.07.2024FDA describes detailed CAPA Procedure in Warning Letter
17.07.2024Congressional Scrutiny on FDA's Foreign Inspection Program puts Pressure on Agency
19.06.2024More FDA Inspections again - also in the EU?
12.06.2024GMP Problems with critical Medicinal Products - what now?
15.05.2024Lack of Quality Oversight: EU Non-Compliance Report issued to Omeprazole Manufacturer